DGAP-News: Hannover Rück SE / Key word(s): Half Year Results Hannover Re posts good half-yearly result 07.08.2013 / 07:30 --------------------------------------------------------------------- Hannover Re posts good half-yearly result - Net premium earned: + 6.3% (currency-adjusted + 7.7%) - Net burden of major losses: EUR 259.5 million (EUR 132.4 million) - Underwriting result in non-life reinsurance + 85.0%: EUR 183.6 million (EUR 99.2 million) - Combined ratio: 94.4% (96.8%) - Investment income - 2.9%: EUR 689.0 million (EUR 709.5 million) - Operating profit (EBIT) + 12.3%: EUR 670.7 million (EUR 597.2 million) - Group net income + 0.6%: EUR 407.7 million (EUR 405.3 million) - Return on equity: 14.0% Hannover, 7 August 2013: With its result for the first half-year Hannover Re has put in place a good basis for achieving its full-year targets. 'The modest rise in Group net income to EUR 408 million was driven mainly by an 85% increase in the underwriting profit for non-life reinsurance', Chief Executive Officer Ulrich Wallin explained. 'This more than made up for the reduced profitability in life and health reinsurance and somewhat lower investment income.' Continued organic growth Gross written premium for the Hannover Re Group increased by 4.9% to reach EUR 7.2 billion (EUR 6.9 billion) as at 30 June 2013. At constant exchange rates growth would have amounted to 6.2%. The level of retained premium remained virtually unchanged at 90.0% (89.8%). Net premium earned climbed 6.3% to EUR 6.2 billion (EUR 5.8 billion), equivalent to growth of 7.7% adjusted for exchange rate effects. Good Group net income The operating profit (EBIT) for the first six months of 2013 was thoroughly pleasing, rising 12.3% to EUR 670.7 million (EUR 597.2 million). Owing to a higher tax ratio Group net income increased less strongly relative to the comparable period, coming in at EUR 407.7 million (EUR 405.3 million). Earnings per share amounted to EUR 3.38 (EUR 3.36). Pleasing result in non-life reinsurance The pace of growth in gross and net premium has slowed in non-life reinsurance. This is due in part to increased competition, but also to the disciplined underwriting policy practised by Hannover Re. 'For reasons of profitability we concentrate our acceptances exclusively on business that meets our margin requirements. We are even prepared to accept a contraction in premium income', Mr. Wallin emphasised. Gross premium in non-life reinsurance increased only slightly relative to the comparable period, rising 0.4% to EUR 4.1 billion (EUR 4.1 billion). At constant exchange rates growth would have come in at 1.3%. The level of retained premium was unchanged at 90.2% (90.2%). Net premium earned climbed 3.0% to EUR 3.4 billion (EUR 3.3 billion); growth of 4.0% would have been recorded after adjustment for exchange rate effects. Following a very calm major loss situation in the first quarter, a number of large losses were recorded in the second quarter. The largest single event was the severe flooding in Germany and other European countries. The resulting net strain for Hannover Re amounts to EUR 136.9 million. Further sizeable losses occurred shortly before the end of the quarter, including for example hail damage in Germany and a flood event in Canada. Total major loss expenditure for Hannover Re as at 30 June 2013 amounted to EUR 259.5 million (EUR 132.4 million). It was only slightly higher than the loss expectancy and hence the major loss budget for the first half-year. The underwriting result for total non-life reinsurance surged by a pleasing 85.0% to EUR 183.6 million (EUR 99.2 million) and thus more than offset the reduced investment income for the business group - a decrease which had been anticipated in view of the low level of interest rates. The combined ratio for the first half-year was positive at 94.4% (96.8%). The operating profit (EBIT) in non-life reinsurance consequently improved by a thoroughly gratifying 27.6% to EUR 549.1 million (EUR 430.3 million) as at 30 June 2013. Group net income increased by 18.6% to EUR 362.1 million (EUR 305.4 million); earnings per share stood at EUR 3.00 (EUR 2.53). Life and health reinsurance offers attractive growth opportunities As anticipated, good business opportunities presented themselves in life and health reinsurance during the first half of the year. The dominant topics here continue to be protection for a progressively ageing population in industrialised nations as well as financially oriented reinsurance solutions designed to optimise a client's capital structure. 'We also booked particularly healthy growth in promising future markets such as Latin America, Eastern Europe and Asia, where demand for our life reinsurance products is especially strong', Mr. Wallin noted. Gross written premium in life and health reinsurance climbed 11.4% to EUR 3.1 billion (EUR 2.8 billion) as at 30 June 2013. New transactions written for the assumption of UK pension business as well as substantial growth in emerging markets were the key factors here. At constant exchange rates growth would have been as high as 13.4%. Net premium earned increased by 10.5% to EUR 2.8 billion (EUR 2.5 billion), equivalent to growth of 12.6% after adjustment for exchange rate effects. Profitability fell short of expectations in the reporting period just ended. This can be attributed principally to losses incurred in part of the book of US mortality business. The operating profit (EBIT) in life and health reinsurance as at 30 June 2013 consequently retreated to EUR 111.4 million (EUR 155.4 million). Group net income closed at EUR 83.8 million (EUR 128.0 million); earnings per share totalled EUR 0.70 (EUR 1.06). Satisfactory investment income Bearing in mind the continued challenging and volatile capital market environment, investments developed in line with expectations. Despite the sustained positive cash flow, the portfolio of investments under own management contracted slightly to EUR 31.6 billion (31 December 2012: EUR 31.9 billion). This was driven by reduced fair values in the portfolio of fixed-income securities due to interest rate increases shortly before the end of the second quarter. Exchange rate effects were an additional factor here. Owing to the protracted low level of interest rates, the ordinary investment income of EUR 503.6 million came in below the comparable period (EUR 532.0 million) as had been expected. Net income from investments under own management contracted in the period under review from EUR 553.2 million to EUR 501.4 million. This was due largely to the balance of unrealised gains and losses: the inflation swaps taken out to hedge part of the inflation risks associated with technical reserves produced an unrealised loss of EUR 39.7 million (EUR -9.9 million) as at 30 June 2013. Altogether, unrealised losses of EUR 37.5 million (EUR +2.9 million) were recognised. The annualised average return on the portfolio of assets under own management amounted to 3.2%. Excluding the aforementioned unrealised effects, the figure was 3.4% and hence within the range of our expectations for the full year. In view of the decline in ordinary and unrealised income in what remained a challenging capital market environment, investment income including interest on funds withheld and contract deposits was still gratifying at EUR 689.0 million (EUR 709.5 million). Shareholders' equity remains robust Hannover Re's equity base remained strong in the first half-year at EUR 5.6 billion (31 December 2012: EUR 6.0 billion). The expected reduction was due to dividend payments as well as interest rate rises on the US side, which led to a decrease in the fair values of investments in this area. The annualised return on equity of 14.0% was comfortably above our minimum target of 750 basis points above risk-free. The total policyholders' surplus (including non-controlling interests and hybrid capital) amounted to EUR 8.5 billion (31 December 2012: EUR 8.9 billion). The book value per share stood at EUR 46.40 (EUR 50.02). Outlook In view of its strong positioning and the development of business to date, Hannover Re expects to post a result in the region of the declared year-end targets in both non-life and life/health reinsurance for the full 2013 financial year. Based on constant exchange rates the company continues to anticipate growth of around 5% in gross premium. In some areas of non-life reinsurance the competitive pressure has continued to intensify relative to the previous year. 'The importance of our strategy of systematic cycle management combined with rigorous underwriting discipline remains undiminished. Going forward, then, we shall continue to write only business that meets our margin requirements', Mr. Wallin emphasised. Despite a more intensely competitive environment, Hannover Re is broadly satisfied with the treaty renewals in non-life reinsurance as at 1 July 2013. Treaties for North American business as well as in the Australian and New Zealand markets traditionally come up for renewal at this time of year. Even though appreciable competitive pressure could be felt in US catastrophe business due to additional capacities from the catastrophe bond market, margins here are for the most part still adequate. However, given that Hannover Re has scaled back the proportion of US property catastrophe business in its non-life reinsurance portfolio to 8%, the implications of this softening market trend for the company are limited. Rate hikes in retail property business, on the other hand, were sustained; in commercial property business, too, Hannover Re booked moderate price increases. For 2013 Hannover Re is looking to grow its gross premium income from total non-life reinsurance by 3% to 5% after adjustment for exchange rate effects. In life and health reinsurance Hannover Re sees good prospects for further profitable growth. Particularly notable growth impetus is anticipated from Asia, India and Eastern Europe, where awareness of the need for individual provision is on the rise. Yet mature markets such as the United States, United Kingdom, Germany and France will also continue to play a pivotal role for Hannover Re. Gross premium is expected to increase by 5% to 7% for the full year after adjustment for exchange rate effects. Growth here could also come in somewhat higher on the basis of the half-year figures. Hannover Re's targeted return on investment for the full year remains unchanged at 3.4%. The results for the first six months constitute a good platform for a continued successful 2013 financial year as well as for attainment of the company's guidance, namely post-tax Group net income in the order of EUR 800 million. This is conditional on the burden of major losses not significantly exceeding the expected level of EUR 625 million for the full year and assumes that there are no unforeseen downturns on capital markets. As for the dividend, Hannover Re continues to aim for a payout ratio in the range of 35% to 40% of its IFRS Group net income after tax. For further information please contact: Corporate Communications: Karl Steinle (tel. +49 511 5604-1500, e-mail: karl.steinle@hannover-re.com) Media Relations: Gabriele Handrick (tel. +49 511 5604-1502, e-mail: gabriele.handrick@hannover-re.com) Investor Relations: Julia Hartmann (tel. +49 511 5604-1529, e-mail: julia.hartmann@hannover-re.com) Please visit: www.hannover-re.com Hannover Re, with a gross premium of EUR 13.8 billion, is the third-largest reinsurer in the world. It transacts all lines of non-life and life and health reinsurance and is present on all continents with around 2,300 staff. The rating agencies most relevant to the insurance industry have awarded Hannover Re very strong insurer financial strength ratings (Standard & Poor's AA- 'Very Strong' and A.M. Best A+ 'Superior'). Please note the disclaimer: www.hannover-re.com/misc/disclaimer-pr-050811 Key figures of the Hannover Re Group (IFRS basis) <pre> in EUR million H1/2013 +/- previous H1/2012 2012 year Hannover Re Group Gross written premium 7,226.7 +4.9% 6,888.4 Net premium earned 6,191.5 +6.3% 5,824.8 Net underwriting result (5.5) (13.2) Net investment income1) 689.0 (2.9%) 709.5 Operating profit / loss (EBIT) 670.7 +12.3% 597.2 Group net income (loss) 407.7 +0.6% 405.3 Earnings per share in EUR 3.38 +0.6% 3.36 Retention 90.0% 89.8% Tax ratio 27.2% 22.9% EBIT margin2) 10.8% 10.3% Return on equity (after tax)3) 14.0% 15.5% in EUR million H1/2013 +/- previous H1/2012 2012 year Policyholders' surplus4) 8,467.5 (5.4%) 8,947.2 Investments (excl. funds held by ceding companies) 31,609.8 (0.8%) 31,874.4 Total assets 55,157.1 +0.6% 54,811.7 Book value per share in EUR 46.40 (7.2%) 50.02 Non-life reinsurance in EUR million H1/2013 +/- previous H1/2012 2012 year Gross written premium 4,097.1 +0.4% 4,079.7 Net premium earned 3,403.9 +3.0% 3,303.4 Net underwriting result 183.6 +85.0% 99.2 Operating profit / loss (EBIT) 549.1 +27.6% 430.3 Group net income (loss) 362.1 +18.6% 305.4 Retention 90.2% 90.2% Combined Ratio1) 94.4% 96.8% EBIT margin2) 16.1% 13.0% Life and health reinsurance in Mio. EUR H1/2013 +/- previous H1/2012 2012 year Gross written premium 3,129.7 +11.4% 2,808.8 Net premium earned 2,787.3 +10.5% 2,521.4 Operating profit / loss (EBIT) 111.4 (28.3%) 155.4 Group net income (loss) 83.8 (34.5%) 128.0 Retention 89.6% 89.2% EBIT margin2) 4.0% 6.2% 1) Including funds withheld 2) Operating result (EBIT) / net premium earned 3) Annualised 4) Equity attributable to shareholders of Hannover Re + non- controlling interests + hybrid capital </pre> Key figures of the Hannover Re Group (IFRS basis) <pre> in EUR million Q2/2013 +/- previous Q2/2012 year Hannover Re Group Gross written premium 3,468.8 +2.7% 3,377.9 Net premium earned 3,110.7 +3.4% 3,008.6 Net underwriting result (22.9) +68.8% (13.6) Net investment income1) 334.3 +24.3% 268.8 Operating profit / loss (EBIT) 318.1 +55.9% 204.0 Group net income (loss) 186.3 +29.4% 144.0 Earnings per share in EUR 1.54 +29.4% 1.19 Retention 90.1% 88.5% Tax ratio 29.0% 18.1% EBIT margin2) 10.2% 6.8% Return on equity (after tax)3) 12.5% 10.7% Non-life reinsurance in EUR million Q2/2013 +/- previous Q2/2012 year Gross written premium 1,899.5 (3.2%) 1,963.1 Net premium earned 1,712.0 (2.1%) 1,748.7 Net underwriting result 85.5 +62.9% 52.5 Operating profit / loss (EBIT) 290.4 +73.6% 167.3 Group net income 187.2 +41.6% 132.3 Retention 90.8% 89.1% Combined Ratio1) 94.8% 96.8% EBIT margin2) 17.0% 9.6% Life and health reinsurance in Mio. EUR Q2/2013 +/- previous Q2/2012 year Gross written premium 1,569.4 +10.9% 1,414.8 Net premium earned 1,398.5 +11.0% 1,259.9 Operating profit / loss (EBIT) 23.1 (30.4%) 33.1 Group net income (loss) 18.6 (33.3%) 27.9 Retention 89.3% 87.6% EBIT margin2) 1.6% 2.6% 1) Including funds withheld 2) Operating result (EBIT) / net premium earned 3) Annualised </pre> End of Corporate News --------------------------------------------------------------------- 07.08.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Hannover Rück SE Karl-Wiechert-Allee 50 30625 Hannover Germany Phone: +49-(0)511-5604-1500 Fax: +49-(0)511-5604-1648 E-mail: info@hannover-re.com Internet: www.hannover-re.com ISIN: DE0008402215 WKN: 840 221 Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard), Hannover; Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart; Terminbörse EUREX End of News DGAP News-Service --------------------------------------------------------------------- 224473 07.08.2013
DGAP-News: Hannover Re posts good half-yearly result
Top 10 Most Recent News Articles
ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up
ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...
Continue Reading
Monster Energy Dominates Skateboard Podium at SLS Paris
Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...
Continue Reading
Monteverde Probes Four Key M&A Deals for Fairness
Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...
Continue Reading
Monteverde's Equity Alert: Scrutinizing Recent M&A Deals
Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...
Continue Reading
Blokees Unveils 90+ New Wonders at Shanghai Fest
A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...
Continue Reading
Lawsuit Highlights Inaction in School Bus Tragedy
Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...
Continue ReadingBlack Culture Icon: Plastic-Covered Couch Takes Stage
A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...
Continue Reading
Power Knot MEA Wins THE BIZZ 2026 for Excellence
Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...
Continue Reading
Class Action Alerts: M&A Under Scrutiny
Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...
Continue Reading
SiBionics and PharmaSens Unveil Diabetes Tech at EASD
Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...
Continue ReadingTop 5 Most Recently Viewed Articles
Understanding Voya Financial's Expected Earnings Results
Voya Financial's Earnings: What to Anticipate Voya Financial (NYSE: VOYA) is on the brink of unveiling its quarterly earnings, and there are important factors for investors to consider ahead of this crucial announcement. Understanding Expectations Analysts project Voya Financial will report an earnings per share (EPS) of $2.24. This figure sets the stage for anticipation...
Continue Reading
Innovative Teddy Bear Aims to Support Autistic Children
New Approach to Comfort for Autistic Children In an inspiring move to support children with autism, an inventor from White Pine has developed an innovative teddy bear, specifically designed to provide comfort and companionship. This creation, known as the Autistic Teddy Bear, emerges from a heartfelt desire to offer a huggable, vibrant friend for children on the autism...
Continue Reading
Shopoff Realty Investments Gains Key Approval for Housing Project
Shopoff Realty Investments Secures Project Approval Shopoff Realty Investments, a notable player in the real estate sector, has received unanimous approval from the local planning commission for its ambitious Euclid + Heil project. This key milestone marks a significant step forward in addressing the housing challenges many communities face today. Overview of the Euclid +...
Continue Reading
Record High New-Vehicle Prices: Kelley Blue Book Insights
Record High for New-Vehicle Average Transaction Prices In a significant milestone for the automotive market, the average transaction price (ATP) for new vehicles in the United States has exceeded $50,000 for the first time, according to recent estimates. This important data sheds light on the ongoing changes and trends influencing vehicle pricing, primarily driven by...
Continue Reading
Cognition Therapeutics Reaches Milestone in Alzheimer’s Study
Cognition Therapeutics Hits Milestone in Alzheimer's Research Cognition Therapeutics, Inc. (NASDAQ: CGTX), based in Purchase, N.Y., recently announced an important milestone in its clinical research for zervimesine (CT1812) as part of the Phase 2 START Study. This study, aimed at addressing early Alzheimer’s disease, has successfully surpassed the 50% enrollment target,...
Continue Reading